Published 2 May 2005. doi:10.1084/jem2019iti3
Rockefeller University Press, 0022-1007 $8.00
JEM, Volume 201, Number 9, 1353-1353
Boosting innate immunity in cancer
|
-GalCerpulsed DCs activate NKT cells and antiviral T cells in advanced cancer patients.
|
|
Mature DCs and the NKT cell ligand
-galactosyl ceramide (
-GalCer) are a promising combination for boosting immunity in humans, according to a study on page 1503. Chang and colleagues used
-GalCerpulsed DCs to immunize cancer patients and showed that the treatment resulted in long-term expansion of both NKT cells and virus-specific CD8+ T cells.
-GalCer, a glycolipid derived from marine sponges, was identified based on its antitumor properties. This foreign glycolipid was later found to be presented to NKT cells by DCs. NKT cells activated by this glycolipid can promote tumor regression in mice. Attempts to extend this work to humans, however, have met with limited success.
-GalCer treatment alone decreased NKT cell numbers in patients with solid tumors, and vaccination with
-GalCerpulsed immature DCs induced only modest and transient NKT cell expansion.
Maturation of the DCstreatment with cytokines that enhance the expression of MHC and costimulatory moleculeswas the key to the approach used by Chang and colleagues. They immunized five advanced cancer patients, none of whom had detectable NKT cells in their blood before treatment. But with
-GalCerpulsed mature DCs, all patients had a rapid and sustained increase in NKT cell numbers.
Surprisingly, CD8+ T cells specific for cytomegalovirus were also expanded by the treatment, suggesting that this approach might also be useful to boost immunity to chronic viral infections like HIV or hepatitis C virus, or to enhance the efficacy of T cellbased vaccines.
Heather L. Van Epps
hvanepps{at}rockefeller.edu

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
Related Article
-
Sustained expansion of NKT cells and antigen-specific T cells after injection of
-galactosyl-ceramide loaded mature dendritic cells in cancer patients
- David H. Chang, Keren Osman, John Connolly, Anjli Kukreja, Joseph Krasovsky, Maggi Pack, Aisha Hutchinson, Matthew Geller, Nancy Liu, Rebecca Annable, Jennifer Shay, Kelly Kirchhoff, Nobusuke Nishi, Yoshitaka Ando, Kunihiko Hayashi, Hani Hassoun, Ralph M. Steinman, and Madhav V. Dhodapkar
J. Exp. Med. 2005 201: 1503-1517.
[Abstract]
[Full Text]
[PDF]